The anti-ischemic effect of synthetic and pharmacologically tested anxiolytic afobazole (10 mg/kg intravenously) was studied on anesthetized rats with acute endocardial ischemia caused by isoproterenol infusion (20 μg/kg/min). A calcium antagonist verapamil (1 mg/kg intravenously) belonging to the group of phenyl alkyl amine derivatives was used as the reference drug. Afobazole and verapamil were shown to exhibit anti-ischemic activity in this experimental model, which was seen from significant decrease in ST segment depression on ECG. The neuroprotective effect of afobazole is to a great extent related to its affinity for σ1 receptors. Therefore, a special series was performed to evaluate the anti-ischemic effect of afobazole after blockade of these receptors with haloperidol (0.5 mg/kg intravenously). Afobazole exhibited no anti-ischemic activity under these conditions. σ1 receptor blockade had no effect on anti-ischemic activity of verapamil. Our results suggest that the agonistic effect of afobazole on σ1 receptors in cardiomyocytes contributes to anti-ischemic activity of this agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S. A. Kryzhanovskii, A. V. Sorokina, V. N. Stolyaruk, et al., Bull. Exp. Biol. Med., 150, No. 3, 284–287 (2010).
S. A. Kryzhanovskii, V. N. Stolyaruk, M. B. Vititnova, et al., Bull. Exp. Biol. Med., 149, No. 3, 314–317 (2010).
S. B. Seredenin and M.V. Voronin, Eksp. Klin. Farmakol., 1, No. 72, 3–11 (2009).
V. N. Stolyaruk, M. B. Vititnova, and S. A. Kryzhanovskii, Vestn. Ros. Aka. Med. Nauk, No. 4, 41–45 (2010).
I. B. Tsorin, I. P. Palka, and G. G. Chichkanov, Eksp. Klin. Farmakol., 72, No. 1, 41–45 (2009).
M. S. Bhuiyan and K. Fukunaga, Exp. Opin. Ther. Targets, 15, No. 2, 144–155 (2011).
J. Cuevas, A. Behensky, W. Deng, and C. Katnik, J. Pharmacol. Exp. Ther., 339, No. 1, 152–160 (2011).
K. Fialova, O. Krizanova, J. Jarkovsky, and M. Novakova, Can. J. Physiol. Pharmacol., 87, No. 12, 1019–1027 (2009).
A. Klouz, M. H. Loueslati, R. Daghfous, and D. Morin, Therapie, 56, No. 5, 557–562 (2001).
A. Lazou, T. Markou, M. Zioga, et al., Physiol. Res., 55, No. 1, 1–8 (2006).
H. K. Lorenzo and S. A. Susin, Drug Resist. Updat., 10, No. 6, 235–255 (2007).
J. Meunier and T. Hayashi, J. Pharmacol. Exp. Ther., 332, No. 2, 388–397 (2010).
K. Vagnerova, P. D. Hurn, A. Bhardwaj, and J. R. Kirsch, Anesth. Analg., 103, No. 2, 430–434 (2006).
S. Yamamoto, K. Matsuki, M. Sasabe, and N. Ohashi, J. Cardiovasc. Pharmacol., 39, No. 2, 234–241 (2002).
J. Zhang, A. Knapton, S. E. Lipshultz, et al., Toxicol. Pathol., 36, No. 2, 277–278 (2008).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 155, No. 6, pp. 723-727, June, 2013
Rights and permissions
About this article
Cite this article
Seredenin, S.B., Tsorin, I.B., Vititnova, M.B. et al. On the Mechanism of Anti-Ischemic Effects of Afobazole. Bull Exp Biol Med 155, 760–763 (2013). https://doi.org/10.1007/s10517-013-2246-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-013-2246-6